David L Paterson

List of Publications by Year
in descending order

427 papers	57,545 citations	1799 103 h-index	1254 226 g-index
432 all docs	432 docs citations	432 times ranked	41678 citing authors

#	Article	IF	Citations
1	Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 318-327.	9.1	3,672
2	Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clinical Infectious Diseases, 2007, 44, 159-177.	5.8	3,390
3	Acinetobacter baumannii : Emergence of a Successful Pathogen. Clinical Microbiology Reviews, 2008, 21, 538-582.	13.6	2,829
4	Extended-Spectrum Î²-Lactamases: a Clinical Update. Clinical Microbiology Reviews, 2005, 18, 657-686.	13.6	2,767
5	Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Annals of Internal Medicine, 2000, 133, 21.	3.9	2,712
6	Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infectious Diseases, The, 2010, 10, 597-602.	9.1	2,485
7	Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infectious Diseases, The, 2013, 13, 785-796.	9.1	1,328
8	Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infectious Diseases, The, 2006, 6, 589-601.	9.1	1,170
9	Critical Care Services and 2009 H1N1 Influenza in Australia and New Zealand. New England Journal of Medicine, 2009, 361, 1925-1934.	27.0	920
10	Antimicrobial Resistance in ESKAPE Pathogens. Clinical Microbiology Reviews, 2020, 33, .	13.6	898
11	Predictors of Mortality in Staphylococcus aureus Bacteremia. Clinical Microbiology Reviews, 2012, 25, 362-386.	13.6	701
12	Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. Journal of Antimicrobial Chemotherapy, 2011, 66, 1-14.	3.0	629
13	Distribution ofLegionellaSpecies and Serogroups Isolated by Culture in Patients with Sporadic Communityâ€Acquired Legionellosis: An International Collaborative Survey. Journal of Infectious Diseases, 2002, 186, 127-128.	4.0	587
14	A Large Outbreak ofClostridium difficileâ€“Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use. Infection Control and Hospital Epidemiology, 2005, 26, 273-280.	1.8	583
15	Mycobacterium tuberculosisInfection in Solidâ€Organ Transplant Recipients: Impact and Implications for Management. Clinical Infectious Diseases, 1998, 27, 1266-1277.	5.8	557
16	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	7.4	538
17	Aspergillus Infections in Transplant Recipients. Clinical Microbiology Reviews, 2005, 18, 44-69.	13.6	536
18	Resistance in Gram-Negative Bacteria: Enterobacteriaceae. American Journal of Medicine, 2006, 119, S20-S28.	1.5	517

#	Article	IF	Citations
19	International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum Î²-Lactamase Production in Nosocomial Infections. Annals of Internal Medicine, 2004, 140, 26.	3.9	515
20	Antibiotic Therapy for Klebsiella pneumoniae Bacteremia: Implications of Production of Extended-Spectrum Â-Lactamases. Clinical Infectious Diseases, 2004, 39, 31-37.	5.8	512
21	Global dissemination of a multidrug resistant Escherichia coli clone. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5694-5699.	7.1	498
22	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 2018, 66, 163-171.	5.8	485
23	Community-Acquired Klebsiella pneumoniae Bacteremia: Global Differences in Clinical Patterns. Emerging Infectious Diseases, 2002, 8, 160-166.	4.3	476
24	Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrobial Agents and Chemotherapy, 2012, 56, 2108-2113.	3.2	468
25	Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center. Antimicrobial Agents and Chemotherapy, 2006, 50, 4114-4123.	3.2	457
26	Setting and Revising Antibacterial Susceptibility Breakpoints. Clinical Microbiology Reviews, 2007, 20, 391-408.	13.6	455
27	â€œCollateral Damageâ€•from Cephalosporin or Quinolone Antibiotic Therapy. Clinical Infectious Diseases, 2004, 38, S341-S345.	5.8	411
28	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infectious Diseases, The, 2021, 21, 226-240.	9.1	411
29	Multidrug-Resistant Bacteria in the Community. Infectious Disease Clinics of North America, 2016, 30, 377-390.	5.1	382
30	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
31	Resistance in gram-negative bacteria: Enterobacteriaceae. American Journal of Infection Control, 2006, 34, S20-S28.	2.3	348
32	Risk Factors, Clinical Characteristics, and Outcome of Nocardia Infection in Organ Transplant Recipients: A Matched Case-Control Study. Clinical Infectious Diseases, 2007, 44, 1307-1314.	5.8	347
33	Invasive Aspergillosis in Transplant Recipients. Medicine (United States), 1999, 78, 123-133.	1.0	328
34	Extended-Spectrum Î²-Lactamases in Klebsiella pneumoniae Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2003, 47, 3554-3560.	3.2	325
35	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients. Clinical Pharmacokinetics, 2011, 50, 99-110.	3.5	325
36	Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial. Clinical Infectious Diseases, 2013, 56, 236-244.	5.8	317

#	Article	IF	Citations
37	Augmented Renal Clearance. Clinical Pharmacokinetics, 2010, 49, 1-16.	3.5	313
38	Therapeutic drug monitoring of Î²-lactams in critically ill patients: proof of concept. International Journal of Antimicrobial Agents, 2010, 36, 332-339.	2.5	305
39	Antibiotic resistanceâ€"Whatâ€™s dosing got to do with it?. Critical Care Medicine, 2008, 36, 2433-2440.	0.9	299
40	The Epidemiological Profile of Infections with Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter Species. Clinical Infectious Diseases, 2006, 43, S43-S48.	5.8	292
41	The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nature Reviews Urology, 2015, 12, 570-584.	3.8	283
42	Community-Associated Extended-Spectrum Î²-Lactamaseâ€"Producing Escherichia coli Infection in the United States. Clinical Infectious Diseases, 2013, 56, 641-648.	5.8	276
43	Therapeutic drug monitoring of antimicrobials. British Journal of Clinical Pharmacology, 2012, 73, 27-36.	2.4	263
44	Opportunistic Infections in 547 Organ Transplant Recipients Receiving Alemtuzumab, a Humanized Monoclonal CD-52 Antibody. Clinical Infectious Diseases, 2007, 44, 204-212.	5.8	250
45	Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2007, 51, 2065-2069.	3.2	244
46	Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant Recipients. Clinical Infectious Diseases, 2003, 36, 46-52.	5.8	228
47	Control of an Outbreak of Infection with the Hypervirulent Clostridium difficile BI Strain in a University Hospital Using a Comprehensive "Bundle" Approach. Clinical Infectious Diseases, 2007, 45, 1266-1273.	5.8	224
48	Can Ceftazidime-Avibactam and Aztreonam Overcome Î²-Lactam Resistance Conferred by Metallo-Î²-Lactamases in Enterobacteriaceae?. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	217
49	Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. Journal of Antimicrobial Chemotherapy, 2006, 59, 128-131.	3.0	216
50	Insights into a Multidrug Resistant Escherichia coli Pathogen of the Globally Disseminated ST131 Lineage: Genome Analysis and Virulence Mechanisms. PLoS ONE, 2011, 6, e26578.	2.5	209
51	Do Human Extraintestinal Escherichia coli Infections Resistant to Expanded-Spectrum Cephalosporins Originate From Food-Producing Animals? A Systematic Review. Clinical Infectious Diseases, 2015, 60, 439-452.	5.8	209
52	New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	208
53	A Multicenter Randomized Trial of Continuous versus Intermittent Î²-Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1298-1305.	5.6	206
54	Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. Journal of Antimicrobial Chemotherapy, 2009, 63, 427-437.	3.0	194

#	Article	IF	Citations
55	Emergence of High Levels of Extended-Spectrum-Î²-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. Antimicrobial Agents and Chemotherapy, 2009, 53, 3280-3284.	3.2	188
56	Antibiotics in the clinical pipeline in October 2019. Journal of Antibiotics, 2020, 73, 329-364.	2.0	188
57	Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infectious Diseases, The, 2009, 9, 245-255.	9.1	185
58	Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infectious Diseases, The, 2010, 10, 395-404.	9.1	178
59	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 731-741.	9.1	174
60	Carbapenemase-Producing Enterobacteriaceae. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 074-084.	2.1	173
61	Dosing guidance for intravenous colistin in critically-ill patients. Clinical Infectious Diseases, 2017, 64, ciw839.	5.8	171
62	Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal Î²-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia. JAMA - Journal of the American Medical Association, 2020, 323, 527.	7.4	169
63	Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study1. Transplantation, 2003, 75, 2023-2029.	1.0	168
64	The Success of Acinetobacter Species; Genetic, Metabolic and Virulence Attributes. PLoS ONE, 2012, 7, e46984.	2.5	165
65	Î²-lactam and Î²-lactamase inhibitor combinations in the treatment of extended-spectrum Î²-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. Lancet Infectious Diseases, The, 2015, 15, 475-485.	9.1	163
66	Aspergillus Galactomannan Antigen in the Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients. Transplantation, 2007, 83, 1330-1336.	1.0	161
67	INVASIVE ASPERGILLOSIS IN LIVER TRANSPLANT RECIPIENTS IN THE 1990s. Transplantation, 1997, 64, 716-720.	1.0	160
68	Multiresistant Gram-negative infections: a global perspective. Current Opinion in Infectious Diseases, 2010, 23, 546-553.	3.1	159
69	Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infectious Diseases, 2015, 15, 516.	2.9	159
70	Th17 Cells Mediate Clade-Specific, Serotype-Independent Mucosal Immunity. Immunity, 2011, 35, 997-1009.	14.3	158
71	In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). Journal of Antimicrobial Chemotherapy, 2005, 55, 965-973.	3.0	155
72	In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.0	155

#	Article	IF	Citations
73	Î²-Lactamase Production in Key Gram-Negative Pathogen Isolates from the Arabian Peninsula. Clinical Microbiology Reviews, 2013, 26, 361-380.	13.6	155
74	Systematic Review and Meta-Analysis of the Significance of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates. Antimicrobial Agents and Chemotherapy, 2011, 55, 405-410.	3.2	152
75	Colistin resistance: a major breach in our last line of defence. Lancet Infectious Diseases, The, 2016, 16, 132-133.	9.1	152
76	Country-to-Country Transfer of Patients and the Risk of Multi-Resistant Bacterial Infection. Clinical Infectious Diseases, 2011, 53, 49-56.	5.8	150
77	ENCEPHALITIS CAUSED BY HUMAN HERPESVIRUS-6 IN TRANSPLANT RECIPIENTS. Transplantation, 2000, 69, 2474-2479.	1.0	149
78	Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania. Antimicrobial Agents and Chemotherapy, 2008, 52, 3837-3843.	3.2	145
79	Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?. Clinical Infectious Diseases, 2016, 62, 552-558.	5.8	145
80	Toward Improved Surveillance: The Impact of Ventilator-Associated Complications on Length of Stay and Antibiotic Use in Patients in Intensive Care Units. Clinical Infectious Diseases, 2013, 56, 471-477.	5.8	141
81	Molecular Characterization of Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae in the Countries of the Gulf Cooperation Council: Dominance of OXA-48 and NDM Producers. Antimicrobial Agents and Chemotherapy, 2014, 58, 3085-3090.	3.2	140
82	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
83	Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. American Journal of Infection Control, 2007, 35, 131-137.	2.3	134
84	Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy: New Challenges in the Era of Multidrug-Resistant Escherichia coli. Clinical Infectious Diseases, 2013, 57, 267-274.	5.8	127
85	Strategies for Reduction in Duration of Antibiotic Use in Hospitalized Patients. Clinical Infectious Diseases, 2011, 52, 1232-1240.	5.8	125
86	Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: A Systematic Review and Meta-analysis. Infection Control and Hospital Epidemiology, 2015, 36, 132-141.	1.8	123
87	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infectious Diseases, The, 2022, 22, 401-412.	9.1	122
88	Simple Disk-Based Method for Detection of Klebsiella pneumoniae Carbapenemase-Type Î²-Lactamase by Use of a Boronic Acid Compound. Journal of Clinical Microbiology, 2008, 46, 4083-4086.	3.9	120
89	A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli. Clinical Infectious Diseases, 2007, 45, 1179-1181.	5.8	119
90	Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolates at a Tertiary Medical Center in Western Pennsylvania. Antimicrobial Agents and Chemotherapy, 2009, 53, 4733-4739.	3.2	116

#	Article	IF	Citations
91	Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae. Scientific Reports, 2015, 5, 15082.	3.3	115
92	Carbapenem Resistance in Klebsiella pneumoniae Due to the New Delhi Metallo-Â-lactamase. Clinical Infectious Diseases, 2011, 52, 481-484.	5.8	114
93	Failure of Current Cefepime Breakpoints To Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative Organisms. Antimicrobial Agents and Chemotherapy, 2007, 51, 4390-4395.	3.2	113
94	Health careâ€“associated pneumonia: identification and initial management in the ED. American Journal of Emergency Medicine, 2008, 26, 1-11.	1.6	112
95	Health Careâ€“Associated Pneumonia (HCAP): A Critical Appraisal to Improve Identification, Management, and Outcomesâ€”Proceedings of the HCAP Summit. Clinical Infectious Diseases, 2008, 46, S296-S334.	5.8	111
96	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. Critical Care, 2015, 19, 28.	5.8	111
97	Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. Nature Communications, 2018, 9, 22.	12.8	111
98	Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula. Antimicrobial Agents and Chemotherapy, 2011, 55, 5134-5142.	3.2	109
99	Escherichia coli Bloodstream Infection After Transrectal Ultrasound-Guided Prostate Biopsy: Implications of Fluoroquinolone-Resistant Sequence Type 131 as a Major Causative Pathogen. Clinical Infectious Diseases, 2012, 54, 1406-1412.	5.8	109
100	Health Risks of Flood Disasters. Clinical Infectious Diseases, 2018, 67, 1450-1454.	5.8	108
101	Infections with Nontyphoidal Salmonella Species Producing TEM-63 or a Novel TEM Enzyme, TEM-131, in South Africa. Antimicrobial Agents and Chemotherapy, 2004, 48, 4263-4270.	3.2	107
102	Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 5685-5695.	3.2	107
103	PREEMPTIVE PROPHYLAXIS WITH A LIPID PREPARATION OF AMPHOTERICIN B FOR INVASIVE FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTS REQUIRING RENAL REPLACEMENT THERAPY1. Transplantation, 2001, 71, 910-913.	1.0	106
104	Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. Journal of Antimicrobial Chemotherapy, 2014, 69, 1972-1980.	3.0	106
105	Identification of IncA/C Plasmid Replication and Maintenance Genes and Development of a Plasmid Multilocus Sequence Typing Scheme. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	106
106	Interactions Between Tacrolimus and Antimicrobial Agents. Clinical Infectious Diseases, 1997, 25, 1430-1440.	5.8	104
107	Risk factors for toxicity in elderly patients given aminoglycosides once daily. Journal of General Internal Medicine, 1998, 13, 735-739.	2.6	104
108	Empirical Antibiotic Choice for the Seriously Ill Patient: Are Minimization of Selection of Resistant Organisms and Maximization of Individual Outcome Mutually Exclusive?. Clinical Infectious Diseases, 2003, 36, 1006-1012.	5.8	104

#	Article	IF	Citations
109	Infective Endocarditis in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 1998, 26, 689-694.	5.8	103
110	Measurement of Adherence to Antiretroviral Medications. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, S103-S106.	2.1	103
111	Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii Isolates in the Gulf Cooperation Council States: Dominance of OXA-23-Type Producers. Journal of Clinical Microbiology, 2015, 53, 896-903.	3.9	103
112	Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials. Journal of Antimicrobial Chemotherapy, 2017, 72, 268-272.	3.0	103
113	Parenteral and Inhaled Colistin for Treatment of Ventilator-Associated Pneumonia. Clinical Infectious Diseases, 2006, 43, S89-S94.	5.8	102
114	Successful Outcome of Human Metapneumovirus (hMPV) Pneumonia in a Lung Transplant Recipient Treated With Intravenous Ribavirin. Journal of Heart and Lung Transplantation, 2007, 26, 862-864.	0.6	102
115	Extensively Drug-ResistantAcinetobacter baumannii. Emerging Infectious Diseases, 2009, 15, 980-982.	4.3	101
116	Coproduction of Novel 16S rRNA Methylase RmtD and Metallo-Î²-Lactamase SPM-1 in a Panresistant Pseudomonas aeruginosa Isolate from Brazil. Antimicrobial Agents and Chemotherapy, 2007, 51, 852-856.	3.2	99
117	CENTRAL NERVOUS SYSTEM LESIONS IN LIVER TRANSPLANT RECIPIENTS. Transplantation, 1998, 66, 1596-1604.	1.0	98
118	Uropathogenic Escherichia coli Mediated Urinary Tract Infection. Current Drug Targets, 2012, 13, 1386-1399.	2.1	97
119	Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid. Antimicrobial Agents and Chemotherapy, 2014, 58, 2334-2343.	3.2	96
120	Integron-mediated Multidrug Resistance in a Global Collection of NontyphoidalSalmonellaentericaIsolates. Emerging Infectious Diseases, 2009, 15, 388-396.	4.3	94
121	Interspecies Spread ofKlebsiella pneumoniaeCarbapenemase Gene in a Single Patient. Clinical Infectious Diseases, 2009, 49, 1736-1738.	5.8	94
122	Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: A bias-adjusted meta-analysis. International Journal of Antimicrobial Agents, 2014, 43, 301-309.	2.5	93
123	Redefining extended-spectrum Â-lactamases: balancing science and clinical need. Journal of Antimicrobial Chemotherapy, 2008, 63, 1-4.	3.0	92
124	CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1. Transplantation, 2000, 70, 717-722.	1.0	89
125	Presence of Plasmid-Mediated Quinolone Resistance in Klebsiella pneumoniae Isolates Possessing bla _{KPC} in the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 2680-2682.	3.2	89
126	Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asiaâ€“Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). International Journal of Antimicrobial Agents, 2010, 36, 408-414.	2.5	89

#	Article	IF	Citations
127	Identification and molecular characterisation of New Delhi metallo-Î²-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. International Journal of Antimicrobial Agents, 2012, 39, 529-533.	2.5	89
128	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
129	Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study. Open Forum Infectious Diseases, 2017, 4, ofx050.	0.9	89
130	Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: Successful combination therapy with voriconazole and terbinafine. Scandinavian Journal of Infectious Diseases, 2007, 39, 87-90.	1.5	88
131	Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. Journal of Infection, 2011, 62, 280-291.	3.3	88
132	An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. Lancet Infectious Diseases, The, 2019, 19, 410-418.	9.1	86
133	Epidemiological Profile of Linezolidâ€Resistant Coagulaseâ€Negative Staphylococci. Clinical Infectious Diseases, 2006, 43, 165-171.	5.8	85
134	The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 5103-5112.	3.2	85
135	Doripenem. Clinical Infectious Diseases, 2009, 49, 291-298.	5.8	84
136	Vancomycin Heteroresistance Is Associated with Reduced Mortality in ST239 Methicillin-Resistant Staphylococcus aureus Blood Stream Infections. PLoS ONE, 2011, 6, e21217.	2.5	84
137	What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. International Journal of Antimicrobial Agents, 2012, 39, 455-457.	2.5	84
138	Outer Membrane Protein Changes and Efflux Pump Expression Together May Confer Resistance to Ertapenem in Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 2006, 50, 2833-2835.	3.2	83
139	Achromobacter Infections and Treatment Options. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	82
140	Multidrug-Resistant Bacteria in the Community. Infectious Disease Clinics of North America, 2020, 34, 709-722.	5.1	81
141	Identification of Novel Vaccine Candidates against Multidrug-Resistant Acinetobacter baumannii. PLoS ONE, 2013, 8, e77631.	2.5	80
142	Association between augmented renal clearance and clinical outcomes in patients receiving Î²-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. International Journal of Antimicrobial Agents, 2017, 49, 624-630.	2.5	80
143	Dominance of IMP-4-Producing Enterobacter cloacae among Carbapenemase-Producing Enterobacteriaceae in Australia. Antimicrobial Agents and Chemotherapy, 2015, 59, 4059-4066.	3.2	78
144	Molecular Epidemiology of Multidrug-Resistant Acinetobacter baumannii in a Single Institution over a 10-Year Period. Journal of Clinical Microbiology, 2010, 48, 4051-4056.	3.9	76

#	Article	IF	Citations
145	The spread and acquisition of NDM-1: a multifactorial problem. Expert Review of Anti-Infective Therapy, 2014, 12, 91-115.	4.4	76
146	Impact of Antibiotic Resistance in Gramâ€Negative Bacilli on Empirical and Definitive Antibiotic Therapy. Clinical Infectious Diseases, 2008, 47, S14-S20.	5.8	74
147	Diagnosis of Human Metapneumovirus Infection in Immunosuppressed Lung Transplant Recipients and Children Evaluated for Pertussis. Journal of Clinical Microbiology, 2007, 45, 548-552.	3.9	73
148	Synergistic killing of NDM-producing MDRKlebsiella pneumoniaeby two â€˜oldâ€™ antibioticsâ€”polymyxin B and chloramphenicol. Journal of Antimicrobial Chemotherapy, 2015, 70, 2589-2597.	3.0	73
149	Detection of plasmid-mediated class C Î²-lactamases. International Journal of Infectious Diseases, 2007, 11, 191-197.	3.3	71
150	Treatment Options for New Delhi Metallo-Beta-Lactamase-Harboring Enterobacteriaceae. Microbial Drug Resistance, 2013, 19, 100-103.	2.0	71
151	High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India. Journal of Antimicrobial Chemotherapy, 2008, 61, 1393-1394.	3.0	68
152	Performance of Various Testing Methodologies for Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus in Bloodstream Isolates. Journal of Clinical Microbiology, 2011, 49, 1489-1494.	3.9	68
153	Molecular Analysis of the Acinetobacter baumannii Biofilm-Associated Protein. Applied and Environmental Microbiology, 2013, 79, 6535-6543.	3.1	68
154	The increased risks of death and extra lengths of hospital and ICU stay from hospital-acquired bloodstream infections: a caseâ€“control study. BMJ Open, 2013, 3, e003587.	1.9	68
155	Risk factors and outcome of extended-spectrum Î²-lactamase-producing Enterobacter cloacae bloodstream infections. International Journal of Antimicrobial Agents, 2011, 37, 26-32.	2.5	66
156	A Change in the Epidemiology of Infections Due to Extended-Spectrum Â-Lactamase–Producing Organisms. Clinical Infectious Diseases, 2006, 42, 935-937.	5.8	65
157	Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1017-1031.	3.3	65
158	Failure to detect chlamydia pneumoniae in atherosclerotic plaques of Australian patients. Pathology, 1998, 30, 169-172.	0.6	64
159	Intrapulmonary Penetration of Voriconazole in Patients Receiving an Oral Prophylactic Regimen. Antimicrobial Agents and Chemotherapy, 2006, 50, 1878-1880.	3.2	64
160	Identification of 16S rRNA Methylase-Producing Acinetobacter baumannii Clinical Strains in North America. Antimicrobial Agents and Chemotherapy, 2007, 51, 4209-4210.	3.2	64
161	Genomic Characteristics of NDM-Producing Enterobacteriaceae Isolates in Australia and Their bla _{NDM} Genetic Contexts. Antimicrobial Agents and Chemotherapy, 2016, 60, 136-141.	3.2	64
162	Editorial Commentary: Looking for Risk Factors for the Acquisition of Antibiotic Resistance: A 21stâ€Century Approach. Clinical Infectious Diseases, 2002, 34, 1564-1567.	5.8	62

#	Article	IF	Citations
163	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 296-306.	3.0	62
164	CAMERA2 â€“ combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials, 2016, 17, 170.	1.6	61
165	Spread of MCR-3 Colistin Resistance in China: An Epidemiological, Genomic and Mechanistic Study. EBioMedicine, 2018, 34, 139-157.	6.1	61
166	Clarithromycin Versus Azithromycin in the Treatment of Mediterranean Spotted Fever in Children: A Randomized Controlled Trial. Clinical Infectious Diseases, 2002, 34, 154-158.	5.8	60
167	Lack of efficacy of mupirocin in the prevention of infections with staphylococcus aureus in liver transplant recipients and candidates1. Transplantation, 2003, 75, 194-198.	1.0	60
168	Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. Clinical Infectious Diseases, 2014, 58, 139-141.	5.8	60
169	Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	60
170	Multiclonal Outbreak of Klebsiella pneumoniae Producing Extended-Spectrum Î²-Lactamase CTX-M-2 and Novel Variant CTX-M-59 in a Neonatal Intensive Care Unit in Brazil. Antimicrobial Agents and Chemotherapy, 2008, 52, 1790-1793.	3.2	59
171	INFECTIOUS COMPLICATIONS OCCURRING IN LIVER TRANSPLANT RECIPIENTS RECEIVING MYCOPHENOLATE MOFETIL. Transplantation, 1998, 66, 593-598.	1.0	58
172	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	1.6	57
173	Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw459.	3.0	57
174	SHV-Type Extended-Spectrum Beta-Lactamase Production Is Associated with Reduced Cefepime Susceptibility in Enterobacter cloacae. Journal of Clinical Microbiology, 2005, 43, 5058-5064.	3.9	56
175	OqxAB, a Quinolone and Olaquindox Efflux Pump, Is Widely Distributed among Multidrug-Resistant Klebsiella pneumoniae Isolates of Human Origin. Antimicrobial Agents and Chemotherapy, 2013, 57, 4602-4603.	3.2	56
176	Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. Journal of Antimicrobial Chemotherapy, 2018, 73, 634-642.	3.0	56
177	Clinical experience with recently approved antibiotics. Current Opinion in Pharmacology, 2006, 6, 486-490.	3.5	55
178	Genotypic and phenotypic identification of Aeromonas species and CphA-mediated carbapenem resistance in Queensland, Australia. Diagnostic Microbiology and Infectious Disease, 2016, 85, 98-101.	1.8	55
179	COVID-19â€"Lessons Learned and Questions Remaining. Clinical Infectious Diseases, 2021, 72, 2225-2240.	5.8	54
180	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. Burns, 2012, 38, 685-690.	1.9	53

#	Article	IF	Citations
181	Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. International Journal of Antimicrobial Agents, 2013, 42, 384-389.	2.5	53
182	Challenges for Standardization of Clostridium difficile Typing Methods. Journal of Clinical Microbiology, 2013, 51, 2810-2814.	3.9	53
183	Long-term morbidity and mortality following bloodstream infection: A systematic literature review. Journal of Infection, 2018, 77, 1-8.	3.3	53
184	Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. Journal of Antimicrobial Chemotherapy, 2011, 66, 2284-2287.	3.0	52
185	Upper Versus Lower Gastrointestinal Delivery for Transplantation of Fecal Microbiota in Recurrent or Refractory Clostridium difficile Infection. Journal of Clinical Gastroenterology, 2017, 51, 145-150.	2.2	52
186	Pulmonary Nodules in Liver Transplant Recipients. Medicine (United States), 1998, 77, 50-58.	1.0	51
187	Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis 1. Clinical Transplantation, 2000, 14, 48-54.	1.6	51
188	Determination of Risk Factors Associated With Isolation of Linezolid-Resistant Strains of Vancomycin-Resistant Enterococcus. Infection Control and Hospital Epidemiology, 2007, 28, 1382-1388.	1.8	51
189	Cost-Effectiveness of a Central Venous Catheter Care Bundle. PLoS ONE, 2010, 5, e12815.	2.5	50
190	Comparable outcomes for Î²-lactam/Î²-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrobial Resistance and Infection Control, 2015, 4, 14.	4.1	50
191	Draft Genome Sequence of NDM-5-Producing Escherichia coli Sequence Type 648 and Genetic Context of bla NDM-5 in Australia. Genome Announcements, 2015, 3, .	0.8	50
192	Multihospital Occurrence of Pan-Resistant Klebsiella pneumoniae Sequence Type 147 with an IS Ecp1 -Directed bla _{OXA-181} Insertion in the mgrB Gene in the United Arab Emirates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	50
193	Antimicrobial treatment challenges in the era of carbapenem resistance. Diagnostic Microbiology and Infectious Disease, 2019, 94, 413-425.	1.8	50
194	Culture-independent detection systems for bloodstream infection. Clinical Microbiology and Infection, 2022, 28, 195-201.	6.0	50
195	Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. Journal of Clinical Virology, 2008, 42, 335-342.	3.1	49
196	In Vitro Susceptibilities of Aerobic and Facultatively Anaerobic Gram-Negative Bacilli Isolated from Patients with Intra-Abdominal Infections Worldwide: 2005 Results from Study for Monitoring Antimicrobial Resistance Trends (SMART). Surgical Infections, 2009, 10, 99-104.	1.4	49
197	Prevalence and molecular characterization of Enterobacteriaceae producing NDM-1 carbapenemase at a military hospital in Pakistan and evaluation of two chromogenic media. Diagnostic Microbiology and Infectious Disease, 2013, 75, 187-191.	1.8	49
198	Characterization of an IncN2-type blaNDM-1-carrying plasmid in Escherichia coli ST131 and Klebsiella pneumoniae ST11 and ST15 isolates in Thailand. Journal of Antimicrobial Chemotherapy, 2014, 69, 3161-3163.	3.0	49

#	Article	IF	Citations
199	Surveillance for antimicrobial resistance in Australian isolates ofClostridium difficile, 2013â€“14. Journal of Antimicrobial Chemotherapy, 2015, 70, 2992-2999.	3.0	49
200	Mechanisms Involved in Acquisition of bla _{NDM} Genes by IncA/C ₂ and IncFII _Y Plasmids. Antimicrobial Agents and Chemotherapy, 2016, 60, 4082-4088.	3.2	49
201	Hospital-wide Eradication of a NosocomialLegionella pneumophilaSerogroup 1 Outbreak. Clinical Infectious Diseases, 2016, 62, 273-279.	5.8	49
202	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2018, 39, 660-667.	1.8	49
203	High Prevalence of Metallo-Î²-Lactamase and 16S rRNA Methylase Coproduction among Imipenem-Resistant Pseudomonas aeruginosa Isolates in Brazil. Antimicrobial Agents and Chemotherapy, 2007, 51, 3388-3390.	3.2	48
204	Molecular Epidemiology and Mechanisms of Carbapenem Resistance ofAcinetobacterspp. in Asia and Oceania. Microbial Drug Resistance, 2015, 21, 424-434.	2.0	48
205	Discovery of mcr-1 -Mediated Colistin Resistance in a Highly Virulent Escherichia coli Lineage. MSphere, 2018, 3, .	2.9	48
206	Effect of Parenteral Antibiotic Administration on Establishment of Intestinal Colonization in Mice by Klebsiella pneumoniae Strains Producing Extended-Spectrum Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2003, 47, 3610-3612.	3.2	47
207	Effect of the Increasing Use of Piperacillin/Tazobactam on the Incidence of Vancomycin-Resistant Enterococci in Four Academic Medical Centers. Infection Control and Hospital Epidemiology, 2004, 25, 380-383.	1.8	47
208	Genetic Contexts of bla _{NDM-1} in Patients Carrying Multiple NDM-Producing Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 7405-7410.	3.2	47
209	Extended-spectrum beta-lactamases: the European experience. Current Opinion in Infectious Diseases, 2001, 14, 697-701.	3.1	46
210	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-Î²-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
211	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	2.9	46
212	Characterization of a Naturally Occurring Class D Î²-Lactamase from Achromobacter xylosoxidans. Antimicrobial Agents and Chemotherapy, 2008, 52, 1952-1956.	3.2	45
213	Clinical Features and Molecular Epidemiology of CMYâ€Type Î²â€Lactamaseâ€“ProducingEscherichia coli. Clinical Infectious Diseases, 2009, 48, 739-744.	5.8	45
214	Control of an Outbreak of Carbapenem-ResistantAcinetobacter baumanniiin Australia after Introduction of Environmental Cleaning with a Commercial Oxidizing Disinfectant. Infection Control and Hospital Epidemiology, 2010, 31, 418-420.	1.8	44
215	Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum Î²-lactamase belonging to ST410 phylogroup A. International Journal of Antimicrobial Agents, 2011, 37, 365-367.	2.5	44
216	Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: dominance of high-risk clones in the region. Journal of Medical Microbiology, 2018, 67, 846-853.	1.8	44

#	Article	IF	Citations
217	Intrapulmonary Disposition of Amphotericin B After Aerosolized Delivery of Amphotericin B Lipid Complex (Abelcet; ABLC) in Lung Transplant Recipients. Transplantation, 2010, 90, 1215-1219.	1.0	43
218	Enhancing Resistance to Cephalosporins in Class C Î²-Lactamases: Impact of Gly214Glu in CMY-2. Biochemistry, 2010, 49, 1014-1023.	2.5	43
219	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiology, 2011, 11, 3.	1.8	43
220	Enhancement of antibiotic-activity through complexation with metal ions - Combined ITC, NMR, enzymatic and biological studies. Journal of Inorganic Biochemistry, 2017, 167, 134-141.	3.5	43
221	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
222	Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and Chemotherapy, 2009, 53, 2700-2701.	3.2	41
223	Escherichia coli ST131 producing CTX-M-15 in Australia. Journal of Antimicrobial Chemotherapy, 2010, 65, 1301-1303.	3.0	41
224	Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study. Vaccine, 2011, 29, 7320-7325.	3.8	41
225	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
226	Modifications in the pmrB gene are the primary mechanism for the development of chromosomally encoded resistance to polymyxins in uropathogenic Escherichia coli. Journal of Antimicrobial Chemotherapy, 2017, 72, 2729-2736.	3.0	41
227	Community-acquired Extended-Spectrum Î²-Lactamase Producers, United States. Emerging Infectious Diseases, 2007, 13, 1121-1123.	4.3	40
228	Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Critical Care, 2009, 13, R35.	5.8	40
229	Expansive spread of IncI1 plasmids carrying blaCMY-2 amongst Escherichia coli. International Journal of Antimicrobial Agents, 2014, 44, 203-208.	2.5	40
230	Bloodstream infections in organ transplant recipients receiving alemtuzumab: No evidence of occurrence of organisms typically associated with profound T cell depletion. Journal of Infection, 2006, 53, 241-247.	3.3	39
231	First Case of Bloodstream Infection Caused by Rhodococcus erythropolis. Journal of Clinical Microbiology, 2009, 47, 2667-2669.	3.9	39
232	Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical Î²-lactam antibiotic therapy be improved?. International Journal of Antimicrobial Agents, 2007, 30, 458-462.	2.5	38
233	Post-transplant Colonization With Non-Aspergillus Molds and Risk of Development of Invasive Fungal Disease in Lung Transplant Recipients. Journal of Heart and Lung Transplantation, 2008, 27, 850-855.	0.6	38
234	Antimicrobial chemotherapy and lung microdialysis: a review. International Journal of Antimicrobial Agents, 2010, 36, 491-500.	2.5	38

#	Article	IF	Citations
235	Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended- Spectrum-Î²-Lactamase-Producing Escherichia coli and the Role of TEM-1 Hyperproduction. Antimicrobial Agents and Chemotherapy, 2011, 55, 495-501.	3.2	38
236	Molecular Epidemiology of NDM-1-Producing Enterobacteriaceae and Acinetobacter baumannii Isolates from Pakistan. Antimicrobial Agents and Chemotherapy, 2014, 58, 5589-5593.	3.2	38
237	Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Scientific Reports, 2015, 5, 12666.	3.3	38
238	Effect of different renal function on antibacterial effects of piperacillin againstPseudomonas aeruginosaevaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy, 2016, 71, 2509-2520.	3.0	38
239	Fracture-related infection: current methods for prevention and treatment. Expert Review of Anti-Infective Therapy, 2020, 18, 307-321.	4.4	38
240	Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy. International Journal of STD and AIDS, 2001, 12, 463-468.	1.1	37
241	Clostridium difficile Infection Seasonality: Patterns across Hemispheres and Continents â€“ A Systematic Review. PLoS ONE, 2015, 10, e0120730.	2.5	37
242	Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum-Î²-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal Unit. Journal of Clinical Microbiology, 2020, 58, .	3.9	37
243	Encephalopathy associated with human herpesvirus 6 in a liver transplant recipient. Liver Transplantation, 1999, 5, 454-455.	1.8	36
244	Optimizing Therapy for Infections Caused by Enterobacteriaceae Producing Extended-Spectrum Î²-Lactamases. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 646-655.	2.1	36
245	Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infectious Diseases, 2013, 13, 376.	2.9	35
246	A New Marker of Sepsis Post Burn Injury?*. Critical Care Medicine, 2014, 42, 2029-2036.	0.9	35
247	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
248	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei. Nature Communications, 2020, 11, 466.	12.8	34
249	Zoonotic Disease in Australia Caused by a Novel Member of the Paramyxoviridae. Clinical Infectious Diseases, 1998, 27, 112-118.	5.8	33
250	Returning to the pre-antibiotic era in the critically ill: The XDR problem*. Critical Care Medicine, 2007, 35, 1789-1791.	0.9	33
251	CTX-M-2â€“ProducingSalmonellaTyphimurium Isolated from Pediatric Patients and Poultry in Brazil. Microbial Drug Resistance, 2009, 15, 317-321.	2.0	33
252	Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries. Antimicrobial Agents and Chemotherapy, 2014, 58, 2126-2134.	3.2	33

#	Article	IF	Citations
253	Multidrug-resistantEscherichia coliin Asia: epidemiology and management. Expert Review of Anti-Infective Therapy, 2015, 13, 575-591.	4.4	33
254	Transmission ofmcr-1-Producing Multidrug-resistant Enterobacteriaceae in Public Transportation in Guangzhou, China. Clinical Infectious Diseases, 2018, 67, S217-S224.	5.8	33
255	Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. International Journal of Antimicrobial Agents, 2020, 55, 105847.	2.5	33
256	Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. Clinical Microbiology and Infection, 2004, 10, 84-85.	6.0	32
257	Acquisition of Rectal Colonization by Vancomycin-Resistant Enterococcus among Intensive Care Unit Patients Treated with Piperacillin-Tazobactam versus Those Receiving Cefepime-Containing Antibiotic Regimens. Antimicrobial Agents and Chemotherapy, 2008, 52, 465-469.	3.2	32
258	New Gram-positive antibiotics. Current Opinion in Infectious Diseases, 2011, 24, 515-520.	3.1	32
259	INTRAOPERATIVE HYPOTHERMIA IS AN INDEPENDENT RISK FACTOR FOR EARLY CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, 1151-1155.	1.0	32
260	The Potential Role of Social Media Platforms in Community Awareness of Antibiotic Use in the Gulf Cooperation Council States: Luxury or Necessity?. Journal of Medical Internet Research, 2015, 17, e233.	4.3	32
261	Guideline of guidelines: management of recurrent urinary tract infections in women. BJU International, 2022, 130, 11-22.	2.5	32
262	Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002â€“2010. International Journal of Antimicrobial Agents, 2013, 41, 224-228.	2.5	31
263	Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
264	Antimicrobial stewardship activities: a survey of Queensland hospitals. Australian Health Review, 2014, 38, 557.	1.1	30
265	An update on cefepime and its future role in combination with novel Î²-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2021, 76, 550-560.	3.0	30
266	Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. Blood Coagulation and Fibrinolysis, 2008, 19, 32-38.	1.0	29
267	Reduced Susceptibility to Cefepime among Escherichia coli Clinical Isolates Producing Novel Variants of CMY-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2009, 53, 3159-3161.	3.2	29
268	Changes in knowledge and attitudes of hospital environmental services staff: The Researching Effective Approaches to Cleaning in Hospitals (REACH) study. American Journal of Infection Control, 2018, 46, 980-985.	2.3	29
269	Pulmonary fungal infections. Current Opinion in Pulmonary Medicine, 2005, 11, 242-246.	2.6	28
270	How Soon Is Now? The Urgent Need for Randomized, Controlled Trials Evaluating Treatment of Multidrugâ€Resistant Bacterial Infection. Clinical Infectious Diseases, 2010, 51, 1245-1247.	5.8	28

#	Article	IF	Citations
271	Researching effective approaches to cleaning in hospitals: protocol of the REACH study, a multi-site stepped-wedge randomised trial. Implementation Science, 2015, 11, 44.	6.9	28
272	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics, 2020, 59, 1195-1216.	3.5	28
273	Budget impact analysis of routinely using whole-genomic sequencing of six multidrug-resistant bacterial pathogens in Queensland, Australia. BMJ Open, 2021, 11, e041968.	1.9	28
274	Serious infections caused by enteric gram-negative bacilli-Mechanisms of antibiotic resistance and implications for therapy of gram-negative sepsis in the transplanted patient. Seminars in Respiratory Infections, 2002, 17, 260-264.	1.3	28
275	In Vitro Susceptibilities ofEscherichia coliIsolated from Patients with Intra-Abdominal Infections Worldwide in 2002â€“2004: Results from SMART (Study for Monitoring Antimicrobial Resistance) Tj ETQq1 1 0.784314 rgBT /Overlock	1.3	28
276	Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review. Surgical Infections, 2012, 13, 9-17.	1.4	27
277	Comparative Genomics and Antimicrobial Resistance Profiling of Elizabethkingia Isolates Reveal Nosocomial Transmission and In Vitro Susceptibility to Fluoroquinolones, Tetracyclines, and Trimethoprim-Sulfamethoxazole. Journal of Clinical Microbiology, 2020, 58, .	3.9	27
278	All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Review of Anti-Infective Therapy, 2022, 20, 707-719.	4.4	27
279	Escherichia coli Isolate Coproducing 16S rRNA Methylase and CTX-M-Type Extended-Spectrum Î²-Lactamase Isolated from an Outpatient in the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 1204-1205.	3.2	26
280	Intercontinental transfer of OXA-181-producing Klebsiella pneumoniae into New Zealand. Journal of Antimicrobial Chemotherapy, 2011, 66, 2888-2890.	3.0	26
281	Community-associated Methicillin-resistant Staphylococcus aureus Causing Orbital Cellulitis in Australian Children. Pediatric Infectious Disease Journal, 2011, 30, 1003-1006.	2.0	26
282	Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a caseâ€“control study. Antimicrobial Resistance and Infection Control, 2017, 6, 14.	4.1	26
283	Oral cephalosporin and Î²-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 2384-2393.	3.0	26
284	Meropenem Administered as a Prolonged Infusion to Treat Serious Gram-Negative Central Nervous System Infections. Pharmacotherapy, 2004, 24, 803-807.	2.6	25
285	MicroPIPE: validating an end-to-end workflow for high-quality complete bacterial genome construction. BMC Genomics, 2021, 22, 474.	2.8	25
286	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. International Journal of Antimicrobial Agents, 2013, 42, 90-93.	2.5	24
287	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 4375-4378.	3.2	24
288	A Case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-Producing Acinetobacterpittii Sequence Type 119 in Australia. Journal of Clinical Microbiology, 2015, 53, 727-730.	3.9	24

#	Article	IF	Citations
289	Assessing control bundles for Clostridium difficile : a review and mathematical model. Emerging Microbes and Infections, 2014, 3, 1-8.	6.5	23
290	Interspecies Transfer of bla _{IMP-4} in a Patient with Prolonged Colonization by IMP-4-Producing Enterobacteriaceae. Journal of Clinical Microbiology, 2014, 52, 3816-3818.	3.9	23
291	Multiplex PCR to detect the genes encoding naturally occurring oxacillinases in Acinetobacter spp.. Journal of Antimicrobial Chemotherapy, 2014, 69, 959-963.	3.0	23
292	Editorial Commentary: The New Acinetobacter Equation: Hypervirulence Plus Antibiotic Resistance Equals Big Trouble: Table 1.. Clinical Infectious Diseases, 2015, 61, 155-156.	5.8	23
293	Comparison of Clostridium difficile Ribotypes Circulating in Australian Hospitals and Communities. Journal of Clinical Microbiology, 2017, 55, 216-225.	3.9	23
294	Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. Current Opinion in Infectious Diseases, 2020, 33, 78-85.	3.1	23
295	Comprehensive analysis of IncC plasmid conjugation identifies a crucial role for the transcriptional regulator AcaB. Nature Microbiology, 2020, 5, 1340-1348.	13.3	23
296	Simkania Negevensis in Bronchoalveolar Lavage of Lung Transplant Recipients: A Possible Association with Acute Rejection. Transplantation, 2007, 83, 138-143.	1.0	22
297	Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2898-2906.	3.0	22
298	Species identification within Acinetobacter calcoaceticusâ€“baumannii complex using MALDI-TOF MS. Journal of Microbiological Methods, 2015, 118, 128-132.	1.6	22
299	Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	22
300	Molecular Analysis of the Simultaneous Production of Two SHV-Type Extended-Spectrum Beta-Lactamases in a Clinical Isolate of Enterobacter cloacae by Using Single-Nucleotide Polymorphism Genotyping. Antimicrobial Agents and Chemotherapy, 2005, 49, 4716-4720.	3.2	21
301	Reducing the Development of Antibiotic Resistance in Critical Care Units. Current Pharmaceutical Biotechnology, 2011, 12, 2062-2069.	1.6	21
302	Replacement of healthcare-associated MRSA by community-associated MRSA in Queensland: Confirmation by genotyping. Journal of Infection, 2013, 67, 439-447.	3.3	21
303	Gramâ€negative resistance: can we combat the coming of a new â€œRed Plagueâ€?. Medical Journal of Australia, 2013, 198, 243-244.	1.7	21
304	A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period. Journal of Infection, 2014, 69, 447-455.	3.3	21
305	Comprehensive analysis of type 1 fimbriae regulation in fimBâ€null strains from the multidrug resistant Escherichia coli ST131 clone. Molecular Microbiology, 2016, 101, 1069-1087.	2.5	21
306	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21

#	Article	IF	Citations
307	Multidrug-Resistant Gram-Negative Pathogens: The Urgent Need for â€˜Oldâ€™ Polymyxins. Advances in Experimental Medicine and Biology, 2019, 1145, 9-13.	1.6	21
308	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	21
309	Cost-effectiveness of an Environmental Cleaning Bundle for Reducing Healthcare-associated Infections. Clinical Infectious Diseases, 2020, 70, 2461-2468.	5.8	21
310	KPC Type B-Lactamase, Rural Pennsylvania. Emerging Infectious Diseases, 2006, 12, 1613-1614.	4.3	20
311	Laboratory-based surveillance of Clostridium difficile circulating in Australia, September â€“ November 2010. Pathology, 2016, 48, 257-260.	0.6	20
312	Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum-Î²-Lactamase- and AmpC-Producing Enterobacterales ?: a Systematic Review and Meta-analysis. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	20
313	Mycobacterium mucogenicum Bacteremia in a Patient With Cirrhosis. Journal of Clinical Gastroenterology, 1998, 27, 346-347.	2.2	20
314	Has the Time Come for Routine Trimethoprim-Sulfamethoxazole Prophylaxis in Patients Taking Biologic Therapies?. Clinical Infectious Diseases, 2013, 56, 1621-1628.	5.8	19
315	Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multiâ€year, multicenter prospective cohort study. Transplant Infectious Disease, 2018, 20, e12877.	1.7	19
316	Genomic analysis of carbapenemase-producing Enterobacteriaceae in Queensland reveals widespread transmission of bla IMP-4 on an IncHI2 plasmid. Microbial Genomics, 2020, 6, .	2.0	19
317	Disseminated Donovanosis (Granuloma Inguinale) Causing Spinal Cord Compression: Case Report and Review of Donovanosis Involving Bone. Clinical Infectious Diseases, 1998, 26, 379-383.	5.8	18
318	Sequence type 131 fimH30 and fimH41 subclones amongst Escherichia coli isolates in Australia and New Zealand. International Journal of Antimicrobial Agents, 2015, 45, 351-358.	2.5	18
319	The use of SWATH to analyse the dynamic changes of bacterial proteome of carbapanemase-producing Escherichia coli under antibiotic pressure. Scientific Reports, 2018, 8, 3871.	3.3	18
320	How urgent is the need for new antifungals?. Expert Opinion on Pharmacotherapy, 2021, 22, 1857-1870.	1.8	18
321	Outbreaks of multidrug-resistant Acinetobacter baumannii strains in a Kenyan teaching hospital. Journal of Global Antimicrobial Resistance, 2014, 2, 190-193.	2.2	17
322	Variation in hospital cleaning practice and process in Australian hospitals: A structured mapping exercise. Infection, Disease and Health, 2017, 22, 195-202.	1.1	17
323	Burkholderia pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	17
324	Emergence of blaOXA-181-carrying ColE plasmid in Klebsiella pneumoniae in Australia. International Journal of Antimicrobial Agents, 2013, 41, 294-296.	2.5	16

#	Article	IF	Citations
325	Risk factors for urinary catheter associated bloodstream infection. Journal of Infection, 2015, 70, 585-591.	3.3	16
326	China's antibiotic resistance problems. Lancet Infectious Diseases, The, 2017, 17, 351-352.	9.1	16
327	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
328	Incidence of community onset MRSA in Australia: least reported where it is Most prevalent. Antimicrobial Resistance and Infection Control, 2019, 8, 33.	4.1	16
329	Evaluation of Meropenemâ€Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. Clinical Pharmacology and Therapeutics, 2021, 109, 1104-1115.	4.7	16
330	Genetic Environment of 16S rRNA Methylase Gene rmtD. Antimicrobial Agents and Chemotherapy, 2008, 52, 2270-2272.	3.2	15
331	Tuberculosis in the Australian Indigenous population: history, current situation and future challenges. Australian and New Zealand Journal of Public Health, 2011, 35, 6-9.	1.8	15
332	25â€Hydroxyvitamin D Concentrations and Clostridium difficile Infection: A Metaâ€Analysis. Journal of Parenteral and Enteral Nutrition, 2017, 41, 890-895.	2.6	15
333	Peripherally InSerted CEntral catheter dressing and securement in patients with cancer: the PISCES trial. Protocol for a 2x2 factorial, superiority randomised controlled trial. BMJ Open, 2017, 7, e015291.	1.9	15
334	Serious Infections in the Intensive Care Unit: Pseudomonas aeruginosa and Acinetobacter baumannii. Clinical Infectious Diseases, 2006, 43, S41-S42.	5.8	14
335	Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTECÂ®: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. Journal of Antimicrobial Chemotherapy, 2008, 62, 1392-1400.	3.0	14
336	Transmission of Bacterial Infections to Healthcare Workers during Intubation and Respiratory Care of Patients with Severe Pneumonia. Infection Control and Hospital Epidemiology, 2009, 30, 1019-1021.	1.8	14
337	Determining research priorities for clinicianâ€initiated trials in infectious diseases. Medical Journal of Australia, 2013, 198, 270-272.	1.7	14
338	Evaluation of the SpeeDx Carba (beta) multiplex real-time PCR assay for detection of NDM, KPC, OXA-48-like, IMP-4-like and VIM carbapenemase genes. BMC Infectious Diseases, 2019, 19, 571.	2.9	14
339	Culture-independent detection of chlorhexidine resistance genes qacA/B and smr in bacterial DNA recovered from body sites treated with chlorhexidine-containing dressings. Journal of Medical Microbiology, 2017, 66, 447-453.	1.8	14
340	Plasmid-Mediated Ciprofloxacin Resistance Imparts a Selective Advantage on Escherichia coli ST131. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0214621.	3.2	14
341	16S ribosomal RNA methylase RmtD produced by Klebsiella pneumoniae in Brazil. Journal of Antimicrobial Chemotherapy, 2008, 61, 746-747.	3.0	13
342	PME-1-Producing Pseudomonas aeruginosa in Qatar. Antimicrobial Agents and Chemotherapy, 2015, 59, 3692-3693.	3.2	13

#	Article	IF	Citations
343	Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis. JAC-Antimicrobial Resistance, 2021, 3, .	2.1	13
344	Rapid detection of NDM and VIM carbapenemase encoding genes by recombinase polymerase amplification and lateral flowâ€“based detection. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2447-2453.	2.9	12
345	Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint. International Journal of Antimicrobial Agents, 2022, 60, 106598.	2.5	12
346	Exacerbated Hyperglycemia Associated with Nelfinavir. Annals of Pharmacotherapy, 1998, 32, 609-610.	1.9	11
347	Skin colonization at peripheral intravenous catheter insertion sites increases the risk of catheter colonization and infection. American Journal of Infection Control, 2019, 47, 1484-1488.	2.3	11
348	Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). Clinical Infectious Diseases, 2019, 68, 1961-1967.	5.8	11
349	Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (â€œMERINO-3â€): study protocol for a multicentre, open-label randomised non-inferiority trial. Trials, 2021, 22, 301.	1.6	11
350	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 1020-1021.	9.1	10
351	Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia. Value in Health, 2020, 23, 994-1002.	0.3	10
352	Transcriptomic responses of a New Delhi metallo-Î²-lactamase-producing Klebsiella pneumoniae isolate to the combination of polymyxin B and chloramphenicol. International Journal of Antimicrobial Agents, 2020, 56, 106061.	2.5	10
353	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent Î²-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 63-68.	0.1	10
354	Morganella morganii, an Emerging Cause of Bloodstream Infections. Microbiology Spectrum, 2022, 10, e0056922.	3.0	10
355	Carriage Duration and Household Transmission of Enterobacterales Producing Extended-Spectrum Beta-Lactamase in the Community: A Systematic Review and Meta-Analysis. Microbial Drug Resistance, 2022, 28, 795-805.	2.0	10
356	Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 2522-2531.	3.0	10
357	Antibiotic-resistant infections in the critically ill adult. Clinics in Laboratory Medicine, 2004, 24, 329-341.	1.4	9
358	An UHPLCâ€“MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. Bioanalysis, 2015, 7, 2311-2319.	1.5	9
359	Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies. Infectious Diseases and Therapy, 2022, 11, 853-870.	4.0	9
360	More Evidence of the Benefits of Rational Antimicrobial Use in Clinical Practice. Infection Control and Hospital Epidemiology, 2003, 24, 642-643.	1.8	8

#	Article	IF	Citations
361	In situprobing the interior of single bacterial cells at nanometer scale. Nanotechnology, 2014, 25, 415101.	2.6	8
362	The Use of Therapeutic Drug Monitoring to Optimize Treatment of Carbapenem-ResistantEnterobacterOsteomyelitis. Microbial Drug Resistance, 2015, 21, 631-635.	2.0	8
363	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
364	Molecular epidemiology of Pseudomonas aeruginosa bloodstream infection isolates in a non-outbreak setting. Journal of Medical Microbiology, 2017, 66, 154-159.	1.8	8
365	Molecular Comparison of Bacterial Communities on Peripheral Intravenous Catheters and Matched Skin Swabs. PLoS ONE, 2016, 11, e0146354.	2.5	8
366	Could a herpesvirus mimic tacrolimus-induced leukoencephalopathy?. Annals of Neurology, 1997, 42, 270-270.	5.3	7
367	Active surveillance for multidrug-resistant Gram-negative bacteria in the intensive care unit. Pathology, 2015, 47, 575-579.	0.6	7
368	Differentiation of Acinetobacter Genomic Species 13BJ/14TU from Acinetobacter haemolyticus by Use of Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry (MALDI-TOF MS): TABLE 1. Journal of Clinical Microbiology, 2015, 53, 3384-3386.	3.9	7
369	Combination antibiotic therapy for Pseudomonas aeruginosa bacteremia in febrile neutropenic patients? The question still remains. Infectious Diseases, 2018, 50, 403-406.	2.8	7
370	Diagnosis of urinary tract infection in older persons in the emergency department: To pee or not to pee, that is the question. EMA - Emergency Medicine Australasia, 2019, 31, 856-862.	1.1	7
371	Optimal Therapy for Multidrug-ResistantAcinetobacter baumannii. Emerging Infectious Diseases, 2010, 16, 171-171.	4.3	6
372	Number of missed doses. Aids, 2012, 26, 1437-1440.	2.2	6
373	Infections Due to Other Members of the Enterobacteriaceae, Including Management of Multidrug-Resistant Strains. , 2012, , 1874-1877.		6
374	A hierarchical spatial modelling approach to investigate MRSA transmission in a tertiary hospital. BMC Infectious Diseases, 2013, 13, 449.	2.9	6
375	Rectal colonization with New Delhi metallo-Â-lactamase-1-producing Escherichia coli prior to transrectal ultrasound (TRUS)-guided prostate biopsy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2957-2959.	3.0	6
376	Community-AcquiredClostridium difficileInfection, Queensland, Australia. Emerging Infectious Diseases, 2016, 22, 1659-1661.	4.3	6
377	Detection of carbapenemase activity in Enterobacteriaceae using LC-MS/MS in comparison with the neo-rapid CARB kit using direct visual assessment and colorimetry. Journal of Microbiological Methods, 2016, 131, 68-72.	1.6	6
378	General Practitioner Antimicrobial Stewardship Programme Study (GAPS): protocol for a cluster randomised controlled trial. BMC Family Practice, 2016, 17, 48.	2.9	6

#	Article	IF	Citations
379	Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infectionsâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 613.	7.4	6
380	Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials, 2021, 22, 889.	1.6	6
381	Pasteurella species bloodstream infections in Queensland, Australia, 2000â€"2019. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 609.	2.9	6
382	Surveillance snapshot of Clostridium difficile infection in hospitals across Queensland detects binary toxin producing ribotype UK 244. Communicable Diseases Intelligence, 2014, 38, E279-84.	0.5	6
383	Sphingomonas paucimobilis bloodstream infection is a predominantly community-onset disease with significant lethality. International Journal of Infectious Diseases, 2022, 119, 172-177.	3.3	6
384	Cryptococcus neoformans infection. Liver Transplantation, 2002, 8, 846-847.	2.4	5
385	Mechanisms of Resistance of Bacteria Causing Ventilator-Associated Pneumonia. Clinics in Chest Medicine, 2005, 26, 75-79.	2.1	5
386	Appropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia. Chest, 2007, 132, 1101-1102.	0.8	5
387	Cefepime MIC Breakpoint Resettlement in Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2009, 53, 337-338.	3.2	5
388	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. International Journal of Antimicrobial Agents, 2009, 34, 383-384.	2.5	5
389	Nanoscale Focused Ion Beam Tomography of Single Bacterial Cells for Assessment of Antibiotic Effects. Microscopy and Microanalysis, 2014, 20, 537-547.	0.4	5
390	Predictors of use of infection control precautions for multiresistant gram-negative bacilli in Australian hospitals: Analysis of a national survey. American Journal of Infection Control, 2014, 42, 963-969.	2.3	5
391	Draft Genome Sequences of Two IMP-4-Producing Escherichia coli Sequence Type 131 Isolates in Australia. Genome Announcements, 2015, 3, .	0.8	5
392	Local acquisition and nosocomial transmission of Klebsiella pneumoniae harbouring the blaNDMâ€1 gene in Australia. Medical Journal of Australia, 2015, 202, 270-271.	1.7	5
393	Evaluation of phenotypic screening tests for carbapenemase production in Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Microbiological Methods, 2015, 111, 105-107.	1.6	5
394	Fosfomycin: what was old is new again. Internal Medicine Journal, 2018, 48, 1425-1429.	0.8	5
395	The risk of resistance: what are the major antimicrobial resistance threats facing Australia?. Medical Journal of Australia, 2019, 211, 103.	1.7	5
396	In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial. Microbiology Spectrum, 2021, 9, e0022621.	3.0	5

#	Article	IF	Citations
397	Modifying Antibiotic Prescribing in Primary Care. Clinical Infectious Diseases, 2006, 42, 1231-1233.	5.8	4
398	A multilevel model of methicillin-resistant Staphylococcus aureus acquisition within the hierarchy of an Australian tertiary hospital. American Journal of Infection Control, 2012, 40, 787-793.	2.3	4
399	The Challenge of Treating Superbugs. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 001-002.	2.1	4
400	Re-activation of varicella zoster virus associated with anterior spinal cord stroke in pregnancy. Infectious Diseases, 2016, 48, 705-707.	2.8	4
401	Reply to Corona and Cattaneo. Clinical Infectious Diseases, 2017, 65, 870-871.	5.8	4
402	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2018, 91, 69-76.	1.8	4
403	OUP accepted manuscript. JAC-Antimicrobial Resistance, 2021, 3, dlab157.	2.1	4
404	Evaluation of quick sequential organ failure assessment and systemic inflammatory response syndrome in patients with gram negative bloodstream infection. Infection, Disease and Health, 2020, 25, 151-157.	1.1	4
405	Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial. JAC-Antimicrobial Resistance, 2022, 4, dlab192.	2.1	4
406	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model. Microbiology Spectrum, 2022, 10, e0052522.	3.0	4
407	The molecular epidemiology of extended-spectrum beta-lactamase producing organisms. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2008, 26, 403.	0.5	3
408	Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae, Northeast Florida. Southern Medical Journal, 2009, 102, 680-687.	0.7	3
409	Bacterial identification using a SCIEX 5800 TOF/TOF MALDI research instrument and an external database. Journal of Microbiological Methods, 2019, 164, 105685.	1.6	3
410	Long term sepsis readmission, mortality and cause of death following Gram negative bloodstream infection: a propensity matched observational linkage study. International Journal of Infectious Diseases, 2022, 114, 34-44.	3.3	3
411	Effect of a Selective Decontamination of the Digestive Tract Regimen Including Parenteral Cefepime on Establishment of Intestinal Colonization with Vancomycin-Resistant Enterococcus spp. and Klebsiella pneumoniae in Mice. Antimicrobial Agents and Chemotherapy, 2006, 50, 2537-2540.	3.2	2
412	Doubtful Model Utility in Predicting High Vancomycin Minimum Inhibitory Concentration Methicillin-Resistant Staphylococcus aureus Bloodstream Infection Episodes. Clinical Infectious Diseases, 2011, 53, 1166-1167.	5.8	2
413	Predominance of VREfm ST203 subgroup in Queensland. Pathology, 2013, 45, 99.	0.6	2
414	Completing the Pictureâ€"Capturing the Resistome in Antibiotic Clinical Trials. Clinical Infectious Diseases, 2021, 72, e1122-e1129.	5.8	2

#	Article	IF	Citations
415	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. Antibiotics, 2021, 10, 100.	3.7	2
416	The Epidemiology of Pan/Extreme Drug Resistance. , 2012, , 27-38.		2
417	An update on cefepime and its future role in combination with novel Î²-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosaâ€“â€”authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2021, 76, 3327-3328.	3.0	2
418	Clostridium Difficile Diarrhoea Associated with Chemotherapy for Ovarian Cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1997, 37, 348-349.	1.0	1
419	Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. Clinical Infectious Diseases, 2020, 71, 433-439.	5.8	1
420	Letter From Australia: A Never-Ending Pandemic?. Annals of Internal Medicine, 2021, , .	3.9	1
421	Cellulitis caused by a multidrugâ€resistant group A streptococcus. Medical Journal of Australia, 1996, 165, 61-62.	1.7	0
422	Infections with Organisms Producing Extended-Spectrum Î²-Lactamase. Issues in Infectious Diseases, 2010, , 21-34.	0.1	0
423	Reply to Soman et al. Clinical Infectious Diseases, 2013, 57, 323-324.	5.8	0
424	Reply to Bonten and Mevius. Clinical Infectious Diseases, 2015, 60, 1867-1868.	5.8	0
425	Reply to Rezahosseini and Nielsen. Clinical Infectious Diseases, 2021, 72, e916-e916.	5.8	0
426	Global Spread of Multidrug-Resistant Gram-Negative Bacilli. , 0, , 213-222.		0
427	Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis. Journal of Clinical Urology, 0, , 205141582210998.	0.1	0